|
Name |
1-Allylcyclopropanecarboxylic acid
|
Molecular Formula | C7H10O2 | |
IUPAC Name* |
1-prop-2-enylcyclopropane-1-carboxylic acid
|
|
SMILES |
C=CCC1(CC1)C(=O)O
|
|
InChI |
InChI=1S/C7H10O2/c1-2-3-7(4-5-7)6(8)9/h2H,1,3-5H2,(H,8,9)
|
|
InChIKey |
YCHKQUJFRCYZQT-UHFFFAOYSA-N
|
|
Synonyms |
1-Allylcyclopropanecarboxylic acid; 80360-57-2; 1-(prop-2-en-1-yl)cyclopropane-1-carboxylic acid; 1-prop-2-enylcyclopropane-1-carboxylic acid; Cyclopropanecarboxylic acid, 1-(2-propenyl)-; SCHEMBL517571; 1-Allylcyclopropanecarboxylicacid; DTXSID80339542; (2-propenyl)cyclopropanecarboxylic; AMY34534; MFCD12026354; ZINC32225553; AKOS006318226; 1-allyl-cyclopropane-1-carboxylic acid; PB47942; TS-01659; CS-0052808; EN300-175757; P17143; F8885-0920
|
|
CAS | 80360-57-2 | |
PubChem CID | 556871 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 126.15 | ALogp: | 1.2 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 37.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 9 | QED Weighted: | 0.587 |
Caco-2 Permeability: | -4.892 | MDCK Permeability: | 0.00001900 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.086 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.423 | Plasma Protein Binding (PPB): | 55.61% |
Volume Distribution (VD): | 0.462 | Fu: | 55.07% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.345 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.132 |
CYP2C9-inhibitor: | 0.035 | CYP2C9-substrate: | 0.088 |
CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.138 |
CYP3A4-inhibitor: | 0.062 | CYP3A4-substrate: | 0.145 |
Clearance (CL): | 1.038 | Half-life (T1/2): | 0.676 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.366 |
Drug-inuced Liver Injury (DILI): | 0.018 | AMES Toxicity: | 0.058 |
Rat Oral Acute Toxicity: | 0.754 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.036 | Carcinogencity: | 0.133 |
Eye Corrosion: | 0.989 | Eye Irritation: | 0.99 |
Respiratory Toxicity: | 0.875 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000639 | 0.323 | D03QIP | 0.250 | ||||
ENC000148 | 0.308 | D0J0ZS | 0.244 | ||||
ENC001220 | 0.267 | D0R3QY | 0.243 | ||||
ENC000896 | 0.256 | D0M8AB | 0.214 | ||||
ENC002417 | 0.238 | D0Z5BC | 0.204 | ||||
ENC000647 | 0.217 | D04CRL | 0.192 | ||||
ENC000058 | 0.214 | D0X7HM | 0.186 | ||||
ENC000022 | 0.214 | D0C6OQ | 0.185 | ||||
ENC003143 | 0.206 | D02FLB | 0.185 | ||||
ENC005922 | 0.203 | D0DZ3X | 0.184 |